This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"Hormone receptor-positive breast cancer (HR+ BCa) is the most frequently diagnosed subtype of breast cancer. Among those diagnosed with this form of cancer, acquired or intrinsic resistance to endocrine therapy represents one of the biggest challenges to treatment. While the androgen receptor has emerged as a promising therapeutic target. studies report conflicting results. Now, new research suggests that blocking certain forms of the androgen receptor prevents the metastatic progression of HR+ BCa. Experiments showed that HR+ BCa cells had elevated amounts of androgen receptors appended with small ubiquitin-like modifiers, or SUMOs. This “SUMOylation” upregulated androgen-receptor- dependent transcriptional activity and gene expression in breast cancer cell lines. Treating these receptors with both the receptor- blocking drug enzalutamide (Enz) and a SUMO inhibitor (GA) decreased the migration and metastasis of breast cancer cells..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"In 2020, approximately 191,930 people were diagnosed with prostate cancer, and an estimated 33,330 people died from the disease. The most common therapies for prostate cancer involve androgen depletion via castration and/or drug treatment. However, the relapse and mortality rates of prostate cancer remain high, prompting a need for less invasive treatments. Now, a growing number of studies suggest that prostate cancer can be inhibited by the hormone melatonin. Melatonin, which is normally associated with the regulation of sleep, can inhibit prostate cancer partly by keeping androgen receptors out of cell nuclei, thus preventing excess androgen signaling and by activating MT1 signaling, ultimately reducing levels of the prostate cancer marker prostate-specific antigen. Melatonin also reduces tumor blood vessel growth and it regulates metabolism, affects differentiation, and induces death in prostate cancer cells..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
No restrictions on your remixing, redistributing, or making derivative works. Give credit to the author, as required.
Your remixing, redistributing, or making derivatives works comes with some restrictions, including how it is shared.
Your redistributing comes with some restrictions. Do not remix or make derivative works.
Most restrictive license type. Prohibits most uses, sharing, and any changes.
Copyrighted materials, available under Fair Use and the TEACH Act for US-based educators, or other custom arrangements. Go to the resource provider to see their individual restrictions.
